{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-135766","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.216369+00:00","generated_at":"2026-05-29T03:58:23.384603+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"aTyr Pharma appoints Eric Benevich to board; amends director compensation policy","bullets":["Eric Benevich appointed as Class II director effective Dec 10, 2024, term through 2026 annual meeting.","Granted option to purchase 100,000 shares at Dec 10 closing price, vesting equally over 36 months.","Amended Non-Employee Director Compensation Policy: annual retainer $40,000; committee fees $5,000–$20,000.","Initial equity grant for new non-employee directors set at 100,000 options; annual grant 50,000 options."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-135766","json":"https://secwatch.observer/filing/0000950170-24-135766.json","markdown":"https://secwatch.observer/filing/0000950170-24-135766.md","text":"https://secwatch.observer/filing/0000950170-24-135766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024135766/0000950170-24-135766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024135766/atyr-20241210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:58:23.384603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}